BRAF and cancer: VC intake was not significantly different between the two groups. Nonetheless, the mean plasma VC level was lower in the cancer group. The cancer group with VC deficiency showed a nonsignificant tendency toward higher mortality. Progression-free survival did not vary based on the presence of VC deficiency. Additionally, patients with BRAF and KRAS mutations did not exhibit significant differences in VC levels.